The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5

Carfilzomib (CFZ) is a second generation proteasome inhibitor approved for the treatment of patients with multiple myeloma. It induces apoptosis in human cancer cells; but the underlying mechanisms remain undefined. In the present study, we show that CFZ decreases the survival of several human cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Bo, Yao, Weilong, Oh, You-Take, Tong, Jing-Shan, Li, Shaohua, Deng, Jiusheng, Yue, Ping, Khuri, Fadlo R., Sun, Shi-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627326/
https://www.ncbi.nlm.nih.gov/pubmed/26009898

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4627326/
https://www.ncbi.nlm.nih.gov/pubmed/26009898

Ejemplares similares